Long-term durability of response to adalimumab in Crohn's disease.

Autores de IIS La Fe

• 

  Pilar Nos Mateu

  Autor

• Joaquin Ernesto Hinojosa De Val

  Autor

• María Andreu Fenoll

  Autor

• María Vilar Palop

  Autor

• Eugenia Saro Perez

  Autor

Participantes ajenos a IIS La Fe

• Chaparro M
• Panés J
• García V
• Merino O
• Domènech E
• Peñalva M
• García-Planella E
• Esteve M
• Muñoz F
• Gutiérrez A
• Mendoza JL
• Barrio J
• Barreiro-de M
• Vera I
• Cabriada JL
• Montoro MA
• Aldeguer X
• Gisbert JP

Grupos

• Enfermedad Inflamatoria Intestinal

Abstract

Adalimumab is an effective treatment for Crohn's disease (CD), but may also be associated with loss of response. Few reports provide insight into the durability of treatment of CD with adalimumab for periods longer than 12 months in clinical practice.

Keywords

• adalimumab; infliximab; intensification; dose escalation; loss of response; Crohn's disease